Vimian Group ABVIMGF 69 Buyback Yield % is -0.75 as of Jul. 02, 2026. GuruFocus rates VIMGF with a GF Score™ of 69/100 and a GF Value™ of $3.29. The stock has 2 warning signs investors should review. Among 89 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 52.81% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Vimian Group AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIMGF vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a Buyback Yield % of -0.75 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vimian Group AB and its competitors. According to the industry distribution chart, Vimian Group AB ranks #42 out of 89 companies in the Medical Diagnostics & Research industry, placing it in the top 47.2%.
Is Vimian Group AB's Buyback Yield % too high?
Vimian Group AB's current Buyback Yield % is -0.75. Based on the distribution chart, Vimian Group AB ranks #42 out of 89 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #42 out of 89 companies for Buyback Yield %. This puts Vimian Group AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Vimian Group AB and its competitors. Vimian Group AB's current Buyback Yield % is -0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Buyback Yield % of -0.75. The stock's GF Value™ is $3.29, compared to a current price of $2.77 — trading 15.8% below its estimated fair value. The current Buyback Yield % is -0.75. Vimian Group AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Buyback Yield % is -0.75 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 15.8% below its estimated GF Value™ of $3.29.
Key valuation signals for VIMGF:
Buyback Yield %: -0.75
GF Value™: $3.29 vs. price of $2.77 (15.8% below fair value)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
69GF Score
Get the complete analysis for VIMGF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
